Key clinical point: Elotuzumab may have synergistic clinical activity with pomalidomide against multiple myeloma.
Major finding: Median progression-free survival was 10.3 months with elotuzumab, pomalidomide, and dexamethasone vs. 4.7 months with pomalidomide and dexamethasone.
Study details: Randomized open-label phase 2 trial of 120 patients with multiple myeloma relapsed or refractory after 2 or more prior lines of therapy.
Disclosures: Bristol-Myers Squibb and AbbVie Biotherapeutics funded the study. Dr. Dimopoulos disclosed honoraria and/or consulting fees from Amgen, BMS, Celgene, Janssen and Takeda.
Source: Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.
Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.
This Week's Must Reads
Must Reads in Multiple Myeloma
Ixazomib improves PFS after myeloma transplant, Dimopoulos MA et al. ASH 2018, Abstract 301